Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma

Clin Nucl Med. 2023 May 1;48(5):426-427. doi: 10.1097/RLU.0000000000004519. Epub 2023 Feb 1.

Abstract

An 84-year-old man with history of metastatic pheochromocytoma/paraganglioma (mPPGL) received surgery 13 years ago, with recent biopsy-proven mPPGL in the T11. 123 I-MIBG scan showed MIBG-avid liver and osseous. Given his medical condition and body habitus (weight, 45 kg; height, 140 cm), the patient was treated with high-specific-activity 131 I-MIBG (Azedra) 300 mCi ×2. He tolerated the medication and was totally asymptomatic. Series 123 I-MIBG scan showed good responses till 22 months after the first treatment at the last visit. This is probably the oldest and smallest adult mPPGL patient treated with Azedra and with prolonged good response.

Publication types

  • Case Reports

MeSH terms

  • 3-Iodobenzylguanidine / therapeutic use
  • Adrenal Gland Neoplasms* / diagnostic imaging
  • Adrenal Gland Neoplasms* / drug therapy
  • Adrenal Gland Neoplasms* / radiotherapy
  • Adult
  • Aged, 80 and over
  • Brain Neoplasms* / drug therapy
  • Humans
  • Male
  • Neoplasms, Second Primary*
  • Paraganglioma* / diagnostic imaging
  • Paraganglioma* / drug therapy
  • Paraganglioma* / radiotherapy
  • Peripheral Nervous System Neoplasms*
  • Pheochromocytoma* / diagnostic imaging
  • Pheochromocytoma* / drug therapy
  • Pheochromocytoma* / radiotherapy

Substances

  • 3-Iodobenzylguanidine